The company expects the topline data from the trial in the later half of 2024. Credit: Orawan Pattarawimonchai/Shutterstock. 

Armata Pharmaceuticals has completed patient enrollment for its Phase II Tailwind study for inhaled bacteriophage therapy AP-PA02, targeting chronic pulmonary Pseudomonas infections. 

The Tailwind study is a pivotal trial that aims to assess the safety, tolerability, and efficacy of AP-PA02 therapy in subjects with non-cystic fibrosis bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P aeruginosa) infection.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The last patient follow-up is scheduled for 7 August 2024. 

Armata anticipates the topline data from the trial in the second half of 2024. 

Armata CEO Dr Deborah Birx said: “In this study, we enrolled a cohort of patients without prior or current inhaled antibiotics, allowing for the evaluation of phage-only therapy compared to placebo, in addition to a cohort of patients receiving inhaled phage plus antibiotics.  

“We look forward to sharing topline data as soon as it becomes available and plan to meet with the FDA shortly thereafter on the design of a pivotal Phase III study, which we are planning to initiate in 2025.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We remain committed to the execution of rigorously designed randomised trials that, if successful, will support registration of our phage candidates.” 

The study’s primary endpoint is the reduction of P aeruginosa in sputum after multiple AP-PA02 doses administered via inhalation. 

Planned across multiple centres, the study is a randomised, double-blind, placebo-controlled trial intended to assess the safety, tolerability, and efficacy of inhaled AP-PA02 as both a monotherapy and in conjunction with inhaled antibiotics.  

Armata chief medical officer Mina Pastagia said: “Notably, the Tailwind study includes an optimised dosing regimen that gives us confidence in our ability to demonstrate clinical safety while evaluating the durability of P aeruginosa reduction in the lungs.”